Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 5548-5548
Author(s):  
Shannon Neville Westin ◽  
Melinda Louie-Gao ◽  
Enkhe Badamgarav ◽  
Mohan V. Bala ◽  
Premal H. Thaker
Keyword(s):  
Risk Factors ◽  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Real World ◽  
Residual Disease ◽  
Stage Iii ◽  
First Line ◽  
Real World Data ◽  
World Data ◽  
Risk Of Death

5548 Background: Limited real-world information is available in ovarian cancer (OC) regarding prognostic factors for disease progression or death after initial treatment. Here, we assessed potential prognostic risk factors in OC patients (pts) who completed first-line (1L) platinum-based chemotherapy (CT) using real-world data. Methods: This retrospective study identified 5535 pts diagnosed with OC from January 2011–October 2018 from the Flatiron database, a longitudinal, demographically and geographically diverse database derived from health records from > 265 cancer clinics and > 2 million US cancer pts. Stage III/IV OC pts who completed 1L platinum-based CT after primary debulking or interval debulking surgery were included. Pts who received a poly(ADP-ribose) polymerase inhibitor (PARPi) in 1L treatment or as maintenance therapy after 1L treatment were excluded. Cox proportional hazards model was used to assess the association between baseline factors (neoadjuvant CT, disease stage, residual disease, BRCA status, ECOG, age, platelet count, hemoglobin, and neutrophil count) and time to next treatment (TTNT; a proxy for progression-free survival) or overall survival (OS) in these pts. Results: 1064 of 5535 pts were eligible per our inclusion/exclusion criteria. Neoadjuvant treatment, stage of disease, residual disease after surgery, and BRCA mutation ( BRCAmut) status were significant prognostic factors for either TTNT or OS. Neoadjuvant chemotherapy pts had a shorter TTNT (hazard ration [HR] = 1.37; P= .001) and OS (HR = 1.64; P= .0002) than pts who underwent primary surgery after adjusting for other covariates. Stage IV pts had a shorter TTNT (HR = 1.26; P= .01) and OS (HR = 1.24; P= .09) than stage III pts. OS was also worse in pts with vs without residual disease (HR = 1.27; P= .04) and worse in BRCAwt than BRCAmut pts (HR = 1.37; P= .10). Conclusions: In this retrospective analysis of a real-world data set, BRCAwt status was associated with higher risk of death. Receipt of neoadjuvant CT, higher stage of disease at diagnosis, or presence of residual disease after surgery were also associated with a shorter TTNT or higher risk of death. These real-world data confirm previously identified prognostic factors.

scholarly journals Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018

2021 ◽  
Author(s):  
Shannon N Westin ◽  
Melinda Louie-Gao ◽  
Divya Gupta ◽  
Premal H Thaker
Keyword(s):  
Risk Factors ◽  
Ovarian Cancer ◽  
Real World ◽  
Advanced Ovarian Cancer ◽  
Stage Iii ◽  
First Line ◽  
Debulking Surgery ◽  
Platinum Based Chemotherapy ◽  
Interval Debulking Surgery ◽  
The Usa

Aim: Patient chart data from the USA during the period of January 2011 through October 2018 were used to assess risk factors for progression in advanced ovarian cancer after response to first-line platinum-based chemotherapy. Patients & methods: Patients with stage III/IV ovarian cancer who completed first-line platinum-based chemotherapy after primary or interval debulking surgery were identified from the Flatiron Health database. Cox proportional hazards modeling was used to assess associations between baseline factors and time to next treatment (TTNT) or overall survival (OS). Results: Patients at stage IV or who received interval debulking surgery had shorter TTNT and OS than patients at stage III or who received primary debulking surgery, respectively. OS was worse in patients with residual disease and in BRCA wild-type. Conclusion: Multiple factors were associated with shorter TTNT or OS in this retrospective real-world analysis.

scholarly journals 1056P Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study

2021 ◽  
Vol 32 ◽  
pp. S881-S882
Author(s):  
I. Marquez-Rodas ◽  
M.A. Berciano Guerrero ◽  
E. Muñoz Couselo ◽  
J.L. Manzano ◽  
G. Crespo Herrero ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Real World ◽  
Advanced Melanoma ◽  
Line Treatment ◽  
First Line ◽  
Real World Data ◽  
World Data ◽  
First Line Treatment

Real-world treatment patterns in patients with advanced (stage III–IV) ovarian cancer in the USA and Europe

2020 ◽  
Vol 16 (15) ◽  
pp. 1013-1030
Author(s):  
Jennifer P Hall ◽  
Jane Chang ◽  
Rebecca Moon ◽  
Olivia Higson ◽  
Katherine Byrne ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Real World ◽  
Parp Inhibitor ◽  
Advanced Ovarian Cancer ◽  
Treatment Decision ◽  
Stage Iii ◽  
Real World Data ◽  
World Data ◽  
Treatment Decision Making ◽  
The Usa

Aim: To analyze real-world data relating to treatment decision-making in stage III–IV ovarian cancer (OC). Materials & methods: Real world data were collected from a survey of physicians and their patients (n = 2413) across Europe and the USA in 2017–2018. Results: 49% had stage IVb disease. 39, 54 and 7% of patients received first-line (1L), second-line, or 7% third-line or later treatment. In the 1L (ongoing or completed), 93% received platinum-containing regimens, 26% bevacizumab-containing regimens and 1% a PARP inhibitor-containing regimen. In 1L maintenance treatment, 81% received bevacizumab, 17% platinum-containing treatments and 6% a PARP inhibitor. Conclusion: The most common 1L treatment for advanced ovarian cancer was platinum-containing chemotherapy. Of those receiving 1L maintenance therapy, 70–99% (across countries) received targeted therapy.

scholarly journals 510 Niraparib outcomes in brca wild-type platinum sensitive recurrent ovarian cancer: a comparison of real-world data to the nova trial

2020 ◽  
Author(s):  
Douglas Cartwright ◽  
Patricia Roxburgh ◽  
Barbara Stanley ◽  
Jennifer Brown ◽  
Alistair Mclaren ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Real World ◽  
Recurrent Ovarian Cancer ◽  
Wild Type ◽  
Real World Data ◽  
World Data ◽  
Platinum Sensitive

CML-296: First-Line Treatment Outcomes of CML Patients in a Real-World Data Setting in Lebanon

2021 ◽  
Vol 21 ◽  
pp. S332-S333
Author(s):  
Fadi Nasr ◽  
Intissar Yehia ◽  
Reem El Khoury ◽  
Saada Diab ◽  
Ahmad Al Ghoche ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
Real World ◽  
Line Treatment ◽  
First Line ◽  
Real World Data ◽  
World Data ◽  
First Line Treatment

First-line and beyond: West Midlands real-world data for EGFR mutant (EGFRm) NSCLC

Lung Cancer ◽  
2020 ◽  
Vol 139 ◽  
pp. S60-S61
Author(s):  
R. Powell ◽  
R. Kussaibati ◽  
A. Khan ◽  
A. Sivapalasuntharam ◽  
P. Wilson ◽  
...  
Keyword(s):  
Real World ◽  
First Line ◽  
Real World Data ◽  
World Data ◽  
West Midlands ◽  
Egfr Mutant

scholarly journals Brain metastases in primary ovarian cancer: Real-world data

2018 ◽  
Vol 29 ◽  
pp. viii338 ◽  
Author(s):  
E. Ratner ◽  
M. Bala ◽  
M. Louie-Gao ◽  
S. Hazard ◽  
P. Brastianos
Keyword(s):  
Ovarian Cancer ◽  
Brain Metastases ◽  
Real World ◽  
Real World Data ◽  
World Data ◽  
Primary Ovarian Cancer

Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: a “Real World” data analysis

2020 ◽  
Author(s):  
Alberto Bongiovanni ◽  
Chiara Liverani ◽  
Flavia Foca ◽  
Valentina Fausti ◽  
Giandomenico Di Menna ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Real World ◽  
Cox Regression ◽  
Propensity Score Analysis ◽  
Objective Response ◽  
Response To Therapy ◽  
Real World Data ◽  
World Data ◽  
Risk Of Death ◽  
Neuroendocrine Neoplasia

Background: Neuroendocrine neoplasia (NEN) are a rare group of tumors with different prognosis and response to therapy. Their heterogeneity is dependent on the site of origin, morphology and Ki67. Temozolomide (TEM) appears to be active in metastatic NENs (mNENs) but there is limited evidence about its efficacy in gastrointestinal NENs. We analyzed “real-world” data on the use of TEM alone or in association with capecitabine (CAPTEM) in patients with mNENs. Patients and Methods: One hundred consecutive patients with advanced NENs treated with TEM or CAPTEM between 2009 and 2019 were included. A pre-treatment tumor growth rate (TGR0) was calculated. Overall survival (OS), progression-free survival (PFS), tolerance, objective response rate (ORR) and disease control rate (DCR) were analyzed. A propensity score analysis and inverse probability of treatment weights for Cox-regression models were used. Results: TEM-based therapy was administered to 95 patients (26.3% CAPTEM and 83.7% TEM) with a median age of 59 years (range 26-85) years. ECOG performance status was 0-2. Carcinoid syndrome was reported in 12 (12.6%) patients. Twenty (21.1%) patients with grade (G) 3 neuroendocrine carcinoma (NEC) and 9 (9.4%) with G3 neuroendocrine tumors (NET) were included in the analysis. Median PFS of the entire group was 10.4 months (95% confidence interval (CI):6.0-11.5). In multivariate analysis, a higher risk of progression was observed for NEC G3 patients (hazard ratio (HR) 2.70, 95%CI:1.25-5.84) and for a TGR ≥19.55 (HR:2.53, 95%CI:1.45-4.40). Median OS was 23.4 months (95%CI: 17.0-29.0) and was similar in both treatment groups (23.9 vs. 20.5 months for TEM and CAPTEM, respectively, p =0.585). In multivariate analysis, TGR ≥19.55 was associated with a higher risk of death (HR:2.18, 95%CI:1.16-4.11) than TGR<19.55, as was NEC G3 (HR: 2.42, 95%CI:1.04-5.59) with respect to NETs. No differences in terms of mPFS or mOS were seen in relation to the primary site of disease. In the 86 patients evaluable for response, ORR was 44.1% and the DCR was 70.9%. Mild adverse events (grade I-II) included anemia, neutropenia and headache. Rare cases of grade 3 neutropenia and thrombocytopenia were recorded. Conclusions: TEM-based regimens are associated with a high DCR and a relatively tolerable toxicity profile in NEN of pancreatic, intestinal and lung origin. Further investigation of these specific NETs is warranted in prospective clinical trials.

Sign in / Sign up

Export Citation Format

Share Document